SEC Form 4 · accession 0001911501-26-000006
Vistagen Therapeutics, Inc. · VTGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas J Williamson
Director
Period of report
Jul 29, 2026
Accepted (ET)
Jul 31, 2026 · 8:56 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001411685
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $0.2433 | Jul 29, 2026 | A | 40,826 | A | — | Jul 29, 2036 | Common Stock | 40,826 | 40,826 | D |
Explanation of responses
- F1Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant.